{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:44:38Z","timestamp":1780634678486,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan","award":["26462689"],"award-info":[{"award-number":["26462689"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s12325-016-0389-3","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T07:28:31Z","timestamp":1468999711000},"page":"1628-1634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy"],"prefix":"10.1007","volume":"33","author":[{"given":"Shino","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2977-124X","authenticated-orcid":false,"given":"Kazuyuki","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ukegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,20]]},"reference":[{"key":"389_CR1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","volume":"363","author":"RN Weinreb","year":"2004","unstructured":"Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711\u201320.","journal-title":"Lancet"},{"key":"389_CR2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313.","journal-title":"Arch Ophthalmol"},{"key":"389_CR3","first-page":"137","volume":"42","author":"M Honjo","year":"2001","unstructured":"Honjo M, Tanihara H, Inatani M, et al. Effects of Rho-associated protein kinase inhibitor, Y-27632, on intraocular pressure outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137\u201344.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"389_CR4","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1167\/iovs.05-1617","volume":"48","author":"H Tokushige","year":"2007","unstructured":"Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216\u201322.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"389_CR5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/02713683.2013.874444","volume":"39","author":"T Isobe","year":"2014","unstructured":"Isobe T, Mizuno K, Kaneko Y, Ohta M, Koide T, Tanabe S. Effects of K-115, a Rho-kinase inhibitor on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39:813\u201322.","journal-title":"Curr Eye Res"},{"key":"389_CR6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, K-115 Clinical Study Group. Phase I clinical trials of a selective Rho kinase inhibitor K-115. JAMA Ophthalmol. 2013;131:1288\u201395.","journal-title":"JAMA Ophthalmol."},{"key":"389_CR7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, K-115 Clinical Study Group. Phase 2 randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731\u20136.","journal-title":"Am J Ophthalmol"},{"key":"389_CR8","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/aos.12599","volume":"93","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M, K-115 Clinical Study Group. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254\u201360.","journal-title":"Acta Ophthalmol"},{"key":"389_CR9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost. JAMA Ophthalmol. 2015;133:755\u201361.","journal-title":"JAMA Ophthalmol."},{"key":"389_CR10","first-page":"52","volume-title":"Clinical detection in glaucoma","author":"E Hodapp","year":"1993","unstructured":"Hodapp E, Parrish RK II, Anderson DR. Clinical detection in glaucoma. St. Louis: Mosby; 1993. p. 52\u201361."},{"key":"389_CR11","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:e26\u201334.","journal-title":"Acta Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0389-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-016-0389-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0389-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:49:10Z","timestamp":1498315750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0389-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,20]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0389-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,20]]}}}